Bristol Myers Squibb (BMY): Pulmonary fibrosis drug admilparant hits Phase 3 goal at 60 mg
Bristol Myers said admilparant met the primary goal in its Phase 3 ALOFT-IPF trial at 60 mg, but the 120 mg dose slowed lung decline without a…
Home/Companies/Bristol Myers Squibb (BMY)
Bristol Myers Squibb (BMY)
2 takes
All Centiview takes on Bristol Myers Squibb (ticker BMY): earnings, deals and market news, newest first. Filed under Healthcare; region: US. Each take lists its sources. For information only, not advice.
Bristol-Myers Squibb (BMY): Leerink cuts rating as pipeline doubts grow
Leerink Partners downgraded Bristol-Myers Squibb to Market Perform, cutting its price target to $59 from $73 — citing fading confidence in three…